866-997-4948(US-Canada Toll Free)

Genital Herpes - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 97 Pages

Genital Herpes - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H2 2017, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape.

Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Herpes - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 3, 17 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Genital Herpes - Overview 6
Genital Herpes - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Genital Herpes - Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Genital Herpes - Companies Involved in Therapeutics Development 23
Abivax SA 23
Admedus Ltd 23
AiCuris GmbH & Co KG 24
Biomere LLC 24
Foamix Pharmaceuticals Ltd 25
Genocea Biosciences Inc 25
GenVec Inc 26
Immune Design Corp 26
JN-International Medical Corp 27
NanoBio Corp 27
NanoViricides Inc 28
Profectus BioSciences Inc 28
Redbiotec AG 29
Sanofi Pasteur SA 29
Starpharma Holdings Ltd 30
Vaccibody AS 30
Vical Inc 31
Genital Herpes - Drug Profiles 32
ABX-196 - Drug Profile 32
acyclovir - Drug Profile 33
Aspidasept - Drug Profile 34
astodrimer - Drug Profile 35
G-103 - Drug Profile 40
GEN-003 - Drug Profile 41
genital herpes (virus like particle) vaccine - Drug Profile 47
genital herpes vaccine - Drug Profile 48
genital herpes vaccine - Drug Profile 51
genital herpes vaccine - Drug Profile 52
genital herpes vaccine - Drug Profile 53
genital herpes vaccine - Drug Profile 54
GV-2207 - Drug Profile 55
herpes simplex virus [type 1, 2] vaccine - Drug Profile 56
herpes simplex virus 2 vaccine - Drug Profile 57
herpes simplex virus 2 vaccine - Drug Profile 58
herpes simplex virus 2 vaccine - Drug Profile 59
herpes simplex virus 2 vaccine - Drug Profile 61
herpes simplex virus 2 vaccine - Drug Profile 62
HSV-529 - Drug Profile 63
NN-001 - Drug Profile 65
pritelivir - Drug Profile 66
Profavax HSV-1 - Drug Profile 69
Profavax HSV-2 - Drug Profile 70
Small Molecule for Genital Herpes - Drug Profile 71
Theravax HSV-1 - Drug Profile 72
Theravax HSV-2 - Drug Profile 73
VCLHB-01 - Drug Profile 74
VCLHM-01 - Drug Profile 76
VMTX-004 - Drug Profile 78
Genital Herpes - Dormant Projects 79
Genital Herpes - Discontinued Products 81
Genital Herpes - Product Development Milestones 82
Featured News & Press Releases 82
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 94
Disclaimer 95

List of Tables
Number of Products under Development for Genital Herpes, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Genital Herpes - Pipeline by Abivax SA, H2 2017
Genital Herpes - Pipeline by Admedus Ltd, H2 2017
Genital Herpes - Pipeline by AiCuris GmbH & Co KG, H2 2017
Genital Herpes - Pipeline by Biomere LLC, H2 2017
Genital Herpes - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017
Genital Herpes - Pipeline by Genocea Biosciences Inc, H2 2017
Genital Herpes - Pipeline by GenVec Inc, H2 2017
Genital Herpes - Pipeline by Immune Design Corp, H2 2017
Genital Herpes - Pipeline by JN-International Medical Corp, H2 2017
Genital Herpes - Pipeline by NanoBio Corp, H2 2017
Genital Herpes - Pipeline by NanoViricides Inc, H2 2017
Genital Herpes - Pipeline by Profectus BioSciences Inc, H2 2017
Genital Herpes - Pipeline by Redbiotec AG, H2 2017
Genital Herpes - Pipeline by Sanofi Pasteur SA, H2 2017
Genital Herpes - Pipeline by Starpharma Holdings Ltd, H2 2017
Genital Herpes - Pipeline by Vaccibody AS, H2 2017
Genital Herpes - Pipeline by Vical Inc, H2 2017
Genital Herpes - Dormant Projects, H2 2017
Genital Herpes - Dormant Projects, H2 2017 (Contd..1), H2 2017
Genital Herpes - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Genital Herpes, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *